Long-term clinical outcomes in critical limb ischemia - A retrospective study of 181 patients

European Review for Medical and Pharmacological Sciences

Volumn 20, Issue 3, 2016, Pages 502-508

  Melillo, E ^a   Micheletti, L ^a   Nuti, M ^a   Dell'omo, G ^a   Berchiolli, R ^a   Adami, D ^a   Farina, A ^b   Panigada, G ^c   Meini, S ^d  

^a UNIVERSITY OF PISA   (Italy)

^b Italfarmaco SpA   (Italy)

^c Santi Cosma e Damiano Hospital   (Italy)

^d SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Critical limb ischemia; Iloprost; Major amputations; Outcome; Survival rate; Transcutaneous gases measurements

Indexed keywords

ILOPROST;

AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; ITALY; LEG AMPUTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; ADVERSE EFFECTS; AMPUTATION; ISCHEMIA; LOWER LIMB; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; SURGERY; TIME FACTOR; TRENDS; VASCULAR SURGERY; VASCULARIZATION;

ADULT; AGED; AMPUTATION; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISCHEMIA; LOWER EXTREMITY; MALE; MIDDLE AGED; MORTALITY; PERIPHERAL ARTERIAL DISEASE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 85017184127     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. NORGREN L, HIATT WR, DORMANDY JA, NEHLER MR, HARRIS KA, FOWKES FG; TASC II Working Group, BELL K, CAPORUSSO J, DURAND-ZALESKI I, KOMORI K, LAMMER J, LIAPIS C, NOVO S, RAZAVI M, ROBBS J, SCHAPER N, SHIGEMATSU H, SAPOVAL M, WHITE C, WHITE J, CLEMENT D, CREAGER M, JAFF M, MOHLER E 3RD, RUTHERFORD RB, SHEEHAN P, SILLESEN H, ROSENFIELD K. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007;33:S1-75.
2. GRESELE P, BUSTI C, FIERRO T. Critical limb ischemia. Intern Emerg Med 2011;6:129-134.
3. MEINI S, MELILLO E, MIGLIACCI R, NICOLOSI G, PANIGADA G, LANDINI G. Peripheral arterial occlusive disease and ischemic disease of the lower limbs are not the same condition. A proposed unambiguous Italian terminology for defining Peripheral arterial disease of lower limbs and related clinical/therapeutic implications. It J Med 2014;8:1-5.
4. VARU VN, HOGG ME, KIBBE MR. Critical limb ischemia. J Vasc Surg 2010;51:230-241.
5. HERNANDO FJS, CONEJERO AM. Peripheral artery disease: pathophysiology, diagnosis and treatment. Rev Esp Cardiol 2007;60:969-982.
6. HIRSCH AT, HASKAL ZJ, HERTZER NR, BAKAL CW, CREAGER MA, HALPERIN JL, HIRATZKA LF, MURPHY WR, OLIN JW, PUSCHETT JB, ROSENFIELD KA, SACKS D, STANLEY JC, TAYLOR LM JR, WHITE CJ, WHITE J, WHITE RA, ANTMAN EM, SMITH SC JR, ADAMS CD, ANDERSON JL, FAXON DP, FUSTER V, GIBBONS RJ, HUNT SA, JACOBS AK, NISHIMURA R, ORNATO JP, PAGE RL, RIEGEL B; AMERICAN ASSOCIATION FOR VASCULAR SURGERY; SOCIETY FOR VASCULAR SURGERY; SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY AND INTERVENTIONS; SOCIETY FOR VASCULAR MEDICINE AND BIOLOGY; SOCIETY OF INTERVENTIONAL RADIOLOGY; ACC/AHA TASK FORCE ON PRACTICE GUIDELINES WRITING COMMITTEE TO DEVELOP GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH PERIPHERAL ARTERIAL DISEASE; AMERICAN ASSOCIATION OF CARDIOVASCULAR AND PULMONARY REHABILITATION; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE; SOCIETY FOR VASCULAR NURSING; TRANSATLANTIC INTER-SOCIETY CONSENSUS; VASCULAR DISEASE FOUNDATION. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation 2006;113:e463-e654.
7. ALONSO-COELLO P, BELLMUNT S, MCGORRIAN C, ANAND SS, GUZMAN R, CRIQUI MH, AKL EA, OLAV VANDVIK P, LANSBERG MG, GUYATT GH, SPENCER FA; AMERICAN COLLEGE OF CHEST PHYSICIANS. Antithrombotic Therapy and Prevention of Thrombosis 9th ed: American College of Chest Physicians. Evidence based clinical practice guidelines. Antithrombotic therapy in peripheral artery disease. Chest 2012;141:e669S-e690S.
8. DI RENZO M, PIERAGALLI D, MEINI S, DE FRANCO V, POMPELLA G, AUTERI A, PASQUI AL. Iloprost treatment reduces TNF-alpha production and TNF-RII expression in critical limb ischemia patients without affecting IL6. Prostaglandins Leukot Essent Fatty Acids 2005;73:405-410.
9. BISCETTI F, GAETANI E, FLEX A, STRAFACE G, PECORINI G, ANGELINI F, STIGLIANO E, APRAHAMIAN T, SMITH RC, CASTELLOT JJ, POLA R. Peroxisome proliferator-activated receptor alpha is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation. J Vasc Res 2009;46:103-108.
10. POLA R, GAETANI E, FLEX A, APRAHAMIAN TR, BOSCH-MARCÉ M, LOSORDO DW, SMITH RC, POLA P. Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator activated receptors. J Mol Cell Cardiol 2004;36:363-370.
11. TOSHIHISA H, MASAYUKI W, YOKOYAMA C, SHIMONISHI M, TANABE T. Prostacyclin-dependent apoptosis mediated by PPARd. J Biol Chem 2001;276:46260-46267.
12. ZHANG J, FU M, ZHU X, XIAO Y, MOU Y, ZHENG H, AKINBAMI MA, WANG Q, CHEN YE. Peroxisome proliferator-activated receptor is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. J Biol Chem 2002;277:11505-11512.
13. CIPOLLONE F, FAZIA M, MINCIONE G, IEZZI A, PINI B, CUCCURULLO C, UCCHINO S, SPIGONARDO F, DI NISIO M, CUCCURULLO F, MEZZETTI A, PORRECA E. Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques. Stroke 2004;35:2253-2257.
14. MEYER-KIRCHRATH J, DEBEY S, GLADORFF C, KIRCHRATH L, SCHROR K. Gene expression profile of the Gscoupled prostcyclin receptor in human vascular smooth muscle cells. Biochem Pharmachol 2004;67:757-765.
15. MEINI S, DE FRANCO V, AUTERI A, SETACCI C, DI RENZO M, PIERAGALLI D. Short-term and long-term effects of one-week treatment with intravenous iloprost in critical limb ischaemia patients (Leriche-Fontaine stage III and IV). Int Angiol 2005;24:64-69.
16. DI STEFANO R, BARSOTTI MC, MELILLO E, IORIO M, SANTONI T, ARMANI C, DELL'OMODARME M, RISTORI C, DE CATERINA R, BALBARINI A. The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia. Thromb Haemost 2008;100:871-877.
17. UK SEVERE LIMB-ISCHAEMIA STUDY GROUP. Treatment of limb threatening ischaemia with intravenous iloprost: a randomized double-blind placebo controlled study. Eur J Vasc Surg 1991;5:511-516.
18. GISAP STUDY GROUP. Evaluation of a conservative treatment with iloprost in severe peripheral occlusive arterial disease. Int Angiol 1994;13:70-74.
19. DORMANDY J, BELCHER G, BROOS P, EIKELBOOM B, LASZLO G, KONRAD P, MOGGI L, MUELLER U. A prospective study of 713 below-knee amputations for ischemia and the effect of a prostacyclin analogue on healing. Br J Surg 1994;81:33-37.
20. DORMANDY J, HEECK L, VIG S. Predicting which patients will develop chronic critical leg ischemia. Semin Vasc Surg 1999;12:138-141.
21. ABOU-ZAMZAM AM, TERUYA TH, KILLEEN JD, BALLARD JL. Major lower extremity amputation in an academic vascular center. Ann Vasc Surg 2003;17:86-90.
22. LOOSEMORE TM, CHALMERS TC, DORMANDY JA. A metaanalysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int Angiol 1994;13:133-142.
23. ALTSTAEDT HO, BERZEWSKI B, BREDDIN HK, BROCKHAUS W, BRUHN HD, CACHOVAN M, DIEHM C, DÖRRLER J, FRANKE CS, GRUSS JD. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukot Essent Fatty Acids 1993;49:573-578.
24. RUFFOLO AJ, ROMANO M, CIAPPONI A. Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev 2010; (1): CD006544.
25. AIELLO A, ANICHINI R, BROCCO E, CARAVAGGI C, CHIAVETTA A, CIONI R, DA ROS R, DE FEO ME, FERRARESI R, FLORIO F, GARGIULO M, GALZERANO G, GANDINI R, GIURATO L, GRAZIANI L, MANCINI L, MANZI M, MODUGNO P, SETACCI C, UCCIOLI L; ITALIAN SOCIETY OF DIABETES; ITALIAN SOCIETY OF RADIOLOGY; ITALIAN SOCIETY OF VASCULAR ENDOVASCULAR SURGERY. Treatment of peripheral arterial disease in diabetes: a consensus of the Italian Societies of Diabetes (SID, AMD), Radiology (SIRM) and Vascular Endovascular Surgery (SICVE). Nutr Metab Cardiovasc Dis 2014;24:355-369.
26. MELILLO E, NUTI M, BALBARINI A. Diagnostic and therapeutical algorhythm in lower critical ischemia where immediate revascularization procedures are impossible. Trends Med 2006;6:207-240.
27. MELILLO E, NUTI M, PEDRINELLI R, BUTTITTA F, BALBARINI A. Is transcutaneous oxygen and carbon dioxide monitoring indispensable in short- and long-term therapeutic management of non-reconstructable lower critical limb ischemia? Minerva Cardioangiol 2006;54:481-498.
28. MELILLO E, NUTI M, BUTTITTA F, BALBARINI A. Medical therapy in critical lower limb ischemia when immediate revascularization is not feasible. G Ital Cardiol (Rome) 2006;7:317-335.